Market News & Trends
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics Inc. recently announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343…
Next-Generation RNA Company Launched by Argobio & University of Southern Denmark
Inverna Therapeutics recently announced its launch as a leading-edge RNA therapeutics company. The Company was co-founded by the University of Southern Denmark and Argobio and…
MBX Biosciences Announces Positive Phase 1 Topline Results for Post-Bariatric Hypoglycemia Treatment
MBX Biosciences, Inc. recently announced positive results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of MBX 1416…
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
RESTEM recently announced the US FDA has granted Fast Track designation for Restem-L, the company’s umbilical cord outer lining stem cells (ULSCs) program for the…
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
Annovis Bio Inc. recently announced the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in…
QUANTRO Therapeutics Achieves Breakthrough in Transcriptomic Drug Discovery
QUANTRO Therapeutics recently announced it has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple…
Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities
Molex, a parent to Phillips Medisize, recently announced it has completed, through an affiliate, the previously announced acquisition of Vectura Group Ltd. (Vectura) from Vectura…
Fortress Biotech & Cyprium Therapeutics Announce FDA Acceptance & Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Fortress Biotech, Inc. and its majority-owned subsidiary, Cyprium Therapeutics, Inc. recently announced the acceptance for review of the New Drug Application (NDA) by the US…
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. recently announced China’s National Medical Products Administration (NMPA) has approved taletrectinib for the treatment of adult patients with locally advanced or metastatic…
Gaelic Laboratories Announces Expansion Enabling Access to Growing Middle East Market
Gaelic Laboratories has established a subsidiary in the UAE, enabling access to the Middle East market – both for Gaelic Laboratories and its marketing partners…
Atavistik Bio Announces Research Collaboration With Pfizer
Atavistik Bio recently announced it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant…
ACELYRIN to Share New Phase 2 Data & Phase 3 Program Design for Subcutaneous Lonigutamab
ACELYRIN, INC. recently announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2…
Immuno-Oncology/Cancer Therapeutics Present Strongest Innovation Pipeline in Next 5 Years
Immuno-oncology (IO) drugs/cancer therapeutics represent one of the most promising areas of medical innovation in the next five years, fundamentally transforming how cancer is treated,…
Eton Pharmaceuticals Advances its Commitment to Rare Disease With Acquisition
Eton Pharmaceuticals, Inc recently announced it has acquired Galzin (zinc acetate). “This acquisition furthers our mission of supporting life-saving treatments for conditions impacting ultra rare…
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
TNF Pharmaceuticals, Inc. recently announced it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhibitor drug…
Recognition of the American Society of Clinical Oncology of the Liver Protective Effect of Can-Fite’s Anti-Cancer Drug Namodenoson
Can-Fite BioPharma Ltd. recently announced that its work titled The Liver Protective Effect of the Anti-Cancer Drug Candidate Namodenoson is Mediated via Adiponectin will be presented…
OBI Pharma Enters Collaboration With GlyTech to Expand GlycOBI Enabling Technologies Outreach in Japan & to Advance Glycan Production
OBI Pharma, Inc. and GlyTech, Inc. have entered into a Marketing Agreement and a Material Transfer Agreement. Under the terms of the Marketing Agreement, OBI…
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule for the Treatment of Obesity & Diabetes
Corxel Pharmaceuticals recently announced the acquisition of CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding…
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Wave Life Sciences Ltd. recently announced the submission of its first clinical trial application (CTA) for WVE-007 in obesity. WVE-007 is an investigational GalNAc-conjugated small…
Ikena Oncology & Inmagene Biopharmaceuticals Announce Agreement for Merger & Private Placement
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals recently announced they have entered into a definitive merger agreement. In connection with the merger, Ikena has entered into…